IN THE FIRST BROAD EXPANSION OF ITS pilot decision-support program for clinical lab testing in Florida, UnitedHealthcare (UHC) will add genetic and molecular tests, drug tests, and pathology procedures, among other assays starting in two months.
On March 1, UHC will expand its laboratory benefit management program in Florida beyond the initial 80 routine anatomical and
CEO SUMMARY: Taken collectively, the growing number of federal investigations of clinical lab companies and health insurer lawsuits against lab companies alleging fraudulent business practices signals a disturbing new trend for the lab industry. Although these allegations are leveled at just a handful of lab companies, the amount of money these labs took out of the system exceeds a billion dollars. Some experts expect payers will enact tough requirements to stop such abuses.
CEO SUMMARY: Cigna was the first national health insurer to require independent board-certified genetic counseling before approving coverage for certain genetic tests. Since launching this program in September 2013, the insurer has seen a 450% increase in genetic counseling for Cigna members. Such counseling has helped to reduce utilization of genetic testing because informed patients understand that a genetic test might not
CEO SUMMARY: Authorities for Eastern Health in Newfoundland and Labrador province in Canada are conducting a root cause analysis after finding discrepancies in breast cancer testing that affected nine patients. Health officials said these cases were discovered as a result of an improved quality assurance testing program and are unrelated to problems that plagued Eastern
How big is the market for laboratory testing in China, with its 20,000 hospitals and population of 1.3 billion people? A new report estimates that the independent clinical laboratory industry in China currently generates about 2 billion Yuan Renminbi per year in revenue. This is equal to about US $315 million. Authors of the report,
In coming weeks, Agendia, probably best known for its genetic breast cancer test, hopes to complete an initial public offering (IPO). Agendia is a company based in Amsterdam, The Netherlands with offices in Irvine, California. Its stock symbol will be “AGDX” and the shares will trade on the Euronext Amsterdam exchange. Plans are to raise
CEO SUMMARY: Newfoundland’s St. John laboratory was rocked by revelations in February that its cyclosporine testing was flawed, exposing patients to the harmful affects from inappropriately high doses of the immunosuppressant drug. Within weeks of this news, the Chief of Laboratory Medicine resigned. Now a team from Toronto’s University Health Network (UHN) is at the
BECKMAN COULTER REPORTS EARNINGS THAT INCLUDE OLYMPUS
THERE WAS A BIG JUMP in fourth quarter revenue at Beckman Coulter Inc., of Brea, California, which increased by 22% over the previous year, to $989.6 million.
This number included $120.2 million in revenue from the recent Olympus Diagnostics acquisition. Beckman Coulter spent $800 million in August 2009 to purchase
CEO SUMMARY: As the closing year of the first decade of the new century and the new millennium, 2009 brought neither disruption nor upheaval to the majority of laboratories in the United States. Rather, it was marked by at least two themes. One was how public disclosure of problems with lab testing services generated media
These days, you hear plenty about Web 2.0 and how it is revolutionizing the way people use the Internet. Pathologist Keith Kaplan, M.D., at the Mayo Clinic uses the term “Pathology 2.0” to describe how use of Web 2.0 technology will similarly transform the anatomic pathology profession. Now comes interesting evidence that Pathology 2.0 is